COVID-19 疫苗的临床建议 - 更新的加强建议

澳大利亚免疫技术咨询小组 (ATAGI) 提供了关于使用加强剂量的 COVID-19 疫苗的最新建议:

  • 建议 18 岁及以上的个人接受单次加强剂量的任一 mRNA 疫苗(辉瑞公司 或者 现代), 初级疫苗接种完成后 3 个月。
  • 建议 16-17 岁的个人在完成主要课程后 3 个月接受单剂 Comirnaty(辉瑞)作为他们的助推器。其他 COVID-19 疫苗品牌未注册用作该年龄段的加强剂量。
  • 同时 Nuvaxovid (Novavax) 未在 TGA 注册用作加强剂量,ATAGI 建议在存在 mRNA 疫苗禁忌症的情况下,可将其用作 18 岁或以上个人的加强剂。支持使用 Nuvaxovid 作为加强剂量的安全性和有效性数据有限,但没有理论上的担忧。
  • Vaxzevria(阿斯利康) 不再推荐用作加强剂量。已经接受 Vaxzevria(阿斯利康)作为加强剂的个人不需要重复服用替代品牌的加强剂。

有关 ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议的更多信息,请参阅以下链接:

ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议

Contemporary Pediatrics: Novavax pediatric COVID-19 vaccine trial yields positive results

Novavax’s protein-based recombinant nanoparticle COVID-19 vaccine NVC-CoV2373 has demonstrated an 80% overall efficacy in paediatric trials against the Delta variant.  

The paediatric trial included 2247 adolescent participants between the ages of 12 to 17 years, of diverse racial and ethnic backgrounds, across 73 sites in the United States.  

“We are encouraged by the results in this adolescent population given the ongoing need for alternative vaccine options for COVID-19,” said Filip Dubovsky, MD, Chief Medical Officer, Novavax, in the statement. 

To read the full press release, follow the link below:
Novavax pediatric COVID-19 vaccine trial yields positive results 

Updated MVEC reference page: Nuvaxovid (Novavax) COVID-19 vaccine

We have updated our Nuvaxovid (Novavax) COVID-19 vaccine page to reflect the latest ATAGI recommendations. The Nuvaxovid (Novavax) COVID-19 vaccine has been provisionally approved by the Therapeutic Goods Administration (TGA) for use in a primary course of vaccination in people aged 18 years and older.

Our reference page also includes links to the latest resources and information regarding the safety and efficacy of the Nuvaxovid (Novavax) COVID-19 vaccine.

To find out more information, please refer to our dedicated MVEC Nuvaxovid (Novavax) COVID-19 vaccine page in the link below.
Updated MVEC reference page: Nuvaxovid (Novavax) COVID-19 vaccine

ATAGI Statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)

Following two phase lll clinical trials conducted in the USA/Mexico and in the UK, the Therapeutic Goods Administration (TGA) has granted provisional approval of the Novavvax COVID-19 vaccine in Australia. 

Novavax COVID-19 vaccine, also known as Nuvaxovid (Biocelect Pty Ltd/Novavax Inc) is a spike protein-based vaccine with each 0.5mL dose containing 5 micrograms of the of SARS-CoV-2 spike protein and 50 micrograms of Matrix-M as an adjuvant.

Novavax COVID-19 vaccine demonstrated to be highly effective in preventing symptomatic COVID-19 disease in adults in a primary schedule. ATAGI continues to monitor the safety, efficacy and immunogenicity data of Novavax COVID-19 vaccine including in high-risk priority groups and will provide updated recommendations as required.  

To read the full ATAGI statement, follow the link below:
ATAGI Statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)